Table1.
Demographic and Clinical Characteristics of Study Patients with Central Sleep Apnea (n=314)
| Characteristics | Heart Failure |
p-value | |
|---|---|---|---|
| Yes (n=118) | No (n=196) | ||
| Age (years) | 75(64, 80) | 65(53, 73) | <0.001 |
| Men | 109(92.4%) | 155(79.1%) | 0.002 |
| White | 109(92.4%) | 174(88.8%) | 0.301 |
| LVEF (%) | 44(35, 59) | 63(59, 66) | 0.001 |
| Body mass index (kg/m2) | 30(27, 36) | 32(28, 36) | 0.560 |
| Smoking | 82(69.5%) | 109(55.6%) | 0.015 |
| Hypertension | 84(71.2%) | 97(49.5%) | <0.001 |
| Diabetes mellitus | 33(28.0%) | 33(16.8%) | 0.019 |
| CAD | 59(50.0%) | 43(21.9%) | <0.001 |
| Cerebrovascular disease | 22(18.6%) | 16(8.2%) | 0.005 |
| Renal disease | 19(16.1%) | 14(7.1%) | 0.012 |
| Iron deficiency anemia | 14(11.9%) | 17(8.7%) | 0.359 |
| Major depressive disorder | 5(4.2%) | 19(9.7%) | 0.078 |
| Parkinson’s disease | 1(0.9%) | 3(1.5%) | 0.601 |
| Medications | |||
| Antiplatelets | 72(61.0%) | 78(39.8%) | <0.001 |
| Diuretics | 50(42.4%) | 30(15.3%) | <0.001 |
| Calcium channel blockers | 10(8.5%) | 21(10.7%) | 0.519 |
| Angiotensin converting enzyme inhibitors /angiotensin II receptor blockers |
59(50.0%) | 51(26.0%) | <0.001 |
| Beta-blockers | 71(60.2%) | 58(29.6%) | <0.001 |
| Ferritin supplements | 6(5.1%) | 4(2.0%) | 0.137 |
| Dopamine agonists | 1(0.9%) | 9(4.6%) | 0.067 |
| Statins | 67(56.8%) | 74(37.8%) | 0.001 |
Data are median (interquartile range) or counts (percentage). Abbreviations: CAD = Coronary artery diseases of angina and myocardial infarction; HF = heart failure; LVEF = left ventricular ejection fraction.